CagriSema’s first major obesity trial produced substantial weight loss, but it also left Novo Nordisk answering questions about how many participants reached the highest dose.
Those questions became the subject of an investor lawsuit. In July 2026, a federal judge allowed part of the case to proceed, finding that investors had sufficiently alleged misleading statements about the trial’s dosing procedures.
Now Novo has a new set of numbers. On September 21, the company reported that a lower dose of its investigational obesity medicine produced 21% estimated weight loss at 68 weeks in the REDEFINE 9 trial, compared with 2% on placebo.
The results are encouraging, but they also create a more complicated question: if a smaller dose can produce substantial weight loss, how much additional benefit does the highest dose provide, and at what cost in tolerability?
Novo plans to present more detailed REDEFINE 9 findings at ObesityWeek on November 15. The headline efficacy result is already public. The fuller interpretation is still ahead.
What the CagriSema REDEFINE 9 Results Already Show
REDEFINE 9 is a Phase 3 clinical trial evaluating two lower once-weekly doses of CagriSema in approximately 300 adults with overweight or obesity.
The doses investigated were 1.0 mg cagrilintide combined with 1.0 mg semaglutide, and 1.7 mg of each component.
Both were evaluated against placebo alongside a reduced-calorie diet and increased physical activity.
The main treatment period lasted 68 weeks. The primary endpoints included the percentage change in body weight and the proportion of participants achieving at least 5% weight loss.
In its September 21 announcement, Novo reported that CagriSema 1.0 mg/1.0 mg produced an estimated 21.0% reduction in body weight, compared with 2.0% for placebo.
The primary superiority endpoint was met.
The company also reported favorable changes in supportive measures including systolic blood pressure, waist-to-height ratio and fasting lipid levels.
But the 21% result comes with an important qualification: it was reported using an efficacy estimand.
That statistical approach estimates the effect under a hypothetical scenario in which participants remained on their assigned treatment as intended.
It is not the same as measuring the average outcome of all participants regardless of treatment discontinuation.
The September announcement did not provide the complete corresponding treatment-policy results, detailed discontinuation rates or the full efficacy findings for the 1.7 mg/1.7 mg group.
On November 4, Novo repeated the 21% REDEFINE 9 result in its third-quarter financial update, reinforcing the importance of the lower-dose program to its development strategy.
The next presentation therefore matters because it may help explain the result, not because the result itself has been kept secret until the meeting.
Why CagriSema Combines Two Different Hormone Pathways
CagriSema combines two peptide-based treatments in a single once-weekly injection.
The first component is semaglutide, the GLP-1 receptor agonist already used in Novo’s Wegovy and Ozempic products.
The second is cagrilintide, an investigational long-acting analogue of amylin.
Amylin is a hormone released by pancreatic beta cells alongside insulin. It contributes to appetite regulation, feelings of fullness and the slowing of gastric emptying.
GLP-1 receptor signaling also influences appetite and food intake, but the two hormones operate through overlapping and distinct biological mechanisms.
Combining them gives Novo a way to target more than one pathway involved in hunger and body-weight regulation.
That is the scientific rationale. The clinical challenge is identifying a dose combination that produces substantial weight loss without creating an unacceptable burden of side effects.
Novo submitted the 2.4 mg/2.4 mg CagriSema combination to the FDA in December 2025, seeking approval for long-term weight management in adults with obesity or qualifying overweight.
The drug remains investigational. Novo said in its October 29 ObesityWeek announcement that CagriSema was not approved in the United States or elsewhere.
The company’s clinical strategy is now broader than proving the full-dose formulation can reduce weight.
It is also trying to understand how different doses might fit the needs of different patients.
The REDEFINE 1 Dosing Controversy Behind the Lawsuit
The controversy began with REDEFINE 1, a pivotal Phase 3 study involving 3,417 adults with obesity or overweight and at least one weight-related complication.
On December 20, 2024, Novo announced the trial’s headline results.
Under the treatment-policy estimand, CagriSema produced 20.4% average weight loss at 68 weeks, compared with 3.0% on placebo.
Under the trial-product estimand, which estimated outcomes assuming participants remained on treatment, the figures were 22.7% versus 2.3%.
Both analyses showed substantial weight loss. But the result fell below the approximately 25% weight-loss expectation that had become associated with the program.
Another detail drew attention.
REDEFINE 1 allowed participants flexibility to modify their dosing throughout the study. At week 68, only 57.3% of the CagriSema group were receiving the highest 2.4 mg/2.4 mg dose.
The finding raised questions about how the flexible dosing protocol, treatment tolerability and expectations established before the trial results influenced investors’ understanding of the program.
Novo’s American depositary receipts fell 17.8% following the December 2024 announcement, according to Reuters.
Investors subsequently filed a securities class action alleging that company statements had misrepresented important aspects of the trial.
On July 28, 2026, US District Judge Robert Kirsch in New Jersey allowed part of that lawsuit to proceed.
The surviving allegations focus on statements by Martin Holst Lange that investors say misleadingly implied that REDEFINE 1 dosing procedures matched those used in earlier clinical trials.
The judge found that the investors had sufficiently pleaded the relevant allegations to survive that stage of litigation.
However, the court dismissed several other claims, including allegations based on Lange’s projection of weight loss of at least 25%, which the judge characterized as aspirational.
The ruling was not a finding that Novo had committed securities fraud.
It determined which allegations could continue through the litigation process.
The distinction matters because a clinical-trial result, a company’s expectations and allegations made in a lawsuit are three different kinds of evidence.
Why Lower Doses Matter Beyond the Headline Number
The commercial argument for lower doses is straightforward.
Not every person receiving an obesity medicine needs the highest available dose, and not every patient can comfortably tolerate it.
Gastrointestinal adverse effects, including nausea, vomiting, diarrhea and constipation, are important considerations for drugs that act through appetite and gastrointestinal signaling pathways.
In REDEFINE 1, the most frequently reported adverse events were gastrointestinal, generally mild to moderate in severity according to Novo.
A lower-dose formulation could become useful if it demonstrates substantial efficacy with acceptable tolerability and practical advantages for patients.
But that possibility should not be confused with a proven result.
The 21% estimate in REDEFINE 9 cannot simply be placed beside the 22.7% trial-product estimate from REDEFINE 1 and used to conclude that the lower dose works almost identically to the full dose.
The studies involved different participants and trial protocols, and the published headline numbers do not constitute a direct randomized comparison between the two dose levels across those studies.
It also remains important to examine treatment discontinuation, gastrointestinal side effects and the proportion of participants who remained on their assigned treatment.
The most useful dose may not always be the one associated with the highest average weight-loss estimate.
For a chronic condition, treatment persistence, safety, tolerability and sustained benefit may ultimately matter as much as the maximum result observed in a trial.
The best dose on paper is not necessarily the best dose for every patient who has to stay on it.
What to Watch at ObesityWeek on November 15
Novo’s October 29 announcement listed a REDEFINE 9 poster presentation for Sunday, November 15, during ObesityWeek 2026 in Washington, D.C.
The poster will cover the effects of the 1.0 mg/1.0 mg and 1.7 mg/1.7 mg combinations in adults with overweight or obesity.
Several details will determine how much the full presentation adds to the already disclosed September results.
The first is the treatment-policy analysis.
Readers need to know how much average weight loss occurred under an analysis accounting for participants who discontinued treatment, rather than relying exclusively on the efficacy estimand.
The second is the complete result for the 1.7 mg/1.7 mg arm.
Does the higher of the two doses provide a meaningful additional benefit, and is that difference accompanied by a change in adverse events or treatment discontinuation?
The third is the placebo-adjusted treatment difference.
The reported 21% versus 2% result corresponds to a numerical difference of approximately 19 percentage points, but the complete statistical analysis is necessary to interpret the precision and robustness of the estimate.
The fourth is tolerability.
Overall and gastrointestinal adverse-event rates, discontinuation rates and dose-escalation details will help show whether lower doses offer an advantage beyond efficacy alone.
The fifth is how frequently participants achieved clinically relevant weight-loss thresholds, including at least 5%, 10%, 15% and 20% reductions in body weight.
The September announcement established that the 1.0 mg/1.0 mg regimen met its primary superiority endpoint against placebo.
The November presentation may help determine how confidently clinicians and regulators can interpret that result across different outcomes and dose levels.
The FDA Decision and the Bigger Commercial Test
Lower-dose data are only one part of Novo Nordisk’s broader CagriSema strategy.
The company submitted the full-dose 2.4 mg/2.4 mg formulation for FDA review in December 2025.
As of November 6, 2026, CagriSema remains investigational, with Novo expecting a US regulatory decision during the fourth quarter.
An FDA approval, if granted, would depend on the agency’s assessment of the complete efficacy, safety and manufacturing evidence supporting the submitted product.
The REDEFINE 9 findings do not automatically establish that both lower-dose combinations will be included in an eventual approved prescribing label.
There is also competition.
Eli Lilly’s tirzepatide remains a major benchmark in obesity treatment, while other investigational medicines are targeting additional hormone pathways and longer dosing intervals.
As Grey Pepper’s coverage of survodutide’s Phase 3 program examines, new obesity medicines must demonstrate not only substantial weight loss but also acceptable tolerability.
That balance also shapes the questions surrounding eloralintide and its potential role alongside established obesity therapies.
CagriSema’s commercial challenge is to show that combining GLP-1 and amylin activity can offer meaningful patient benefits that justify its place in an increasingly crowded market.
The 21% lower-dose result strengthens the evidence that the combination remains pharmacologically active at doses below the full 2.4 mg/2.4 mg formulation.
It does not settle whether those doses provide superior tolerability, how they compare directly with the full dose or what regulators will ultimately allow the company to market.
Nor does it resolve the investor lawsuit over what was said about REDEFINE 1 before the original results were announced.
Those are separate questions requiring different evidence.
Novo now has encouraging lower-dose efficacy data. The next test is whether the complete dataset shows that dose flexibility translates into a meaningful clinical advantage.
The original controversy was about what investors were told concerning dosing. The next scientific question is what different doses actually deliver.
Sources and Further Reading
- Novo Nordisk: REDEFINE 9 and REIMAGINE 5 Topline Results, September 21, 2026.
- Novo Nordisk: CagriSema and Wegovy Data at ObesityWeek 2026, October 29, 2026.
- Novo Nordisk: Third-Quarter 2026 Financial Results and Pipeline Update, November 4, 2026.
- Novo Nordisk: REDEFINE 1 Phase 3 Headline Results, December 20, 2024.
- Reuters: Novo Nordisk Must Face US Shareholder Lawsuit Over CagriSema Trial, July 28, 2026.
- UK Health Research Authority: REDEFINE 9 Research Summary, NCT06388187.
- Novo Nordisk: CagriSema FDA Submission, December 18, 2025.
